Phase I study of weekly anti-insulin-like growth factor-I receptor (IGF-IR) monoclonal antibody IMC-A12 in patients with advanced solid tumors who no longer respond to standard therapy or for whom no standard therapy is available.

Trial Profile

Phase I study of weekly anti-insulin-like growth factor-I receptor (IGF-IR) monoclonal antibody IMC-A12 in patients with advanced solid tumors who no longer respond to standard therapy or for whom no standard therapy is available.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Oct 2015

At a glance

  • Drugs Cixutumumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors ImClone Systems
  • Most Recent Events

    • 17 Dec 2010 Planned End Date changed from 1 Dec 2010 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 22 Sep 2010 Planned end date changed from 1 Sep 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 28 Oct 2009 Actual patient number (24) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top